F
Florian M.E. Wagenlehner
Researcher at University of Giessen
Publications - 430
Citations - 11127
Florian M.E. Wagenlehner is an academic researcher from University of Giessen. The author has contributed to research in topics: Medicine & Prostatitis. The author has an hindex of 50, co-authored 389 publications receiving 8880 citations. Previous affiliations of Florian M.E. Wagenlehner include University Hospital of Giessen and Marburg & Technische Universität München.
Papers
More filters
Guidelines on Urological Infections
Magnus Grabe,Riccardo Bartoletti,T. Tony Cai,Béla Köves,Peter Tenke,Florian M.E. Wagenlehner,Björn Wullt +6 more
TL;DR: It is essential to limit the use of antibiotics in general and fluoroquinolones and cephalosporins in particular, especially in uncomplicated infections and asymptomatic bacteriuria.
Journal ArticleDOI
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
TL;DR: Treatment with ceftolozane-tazobactam led to better responses than high-dose levofloxacin in patients with complicated lower-urinary-tract infections or pyelonephritis and superiority was indicated.
Journal ArticleDOI
Infective Complications After Prostate Biopsy: Outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, A Prospective Multinational Multicentre Prostate Biopsy Study
Florian M.E. Wagenlehner,Edgar van Oostrum,Peter Tenke,Zafer Tandogdu,Mete Cek,Magnus Grabe,Björn Wullt,Robert Pickard,Kurt G. Naber,Adrian Pilatz,Wolfgang Weidner,Truls E. Bjerklund-Johansen +11 more
TL;DR: Infective complications after transrectal P-Bx are important because of the associated patient morbidity, and the study confirms a high incidence of fluoroquinolone resistance in causative bacteria.
Journal ArticleDOI
Ceftazidime-Avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M.E. Wagenlehner,Jack D. Sobel,Paul Newell,Jon Armstrong,Xiangning Huang,Gregory G. Stone,Katrina Yates,Leanne B. Gasink +7 more
TL;DR: Ceftazidime-avibactam was highly effective for empiric treatment of complicated urinary tract infection, including in patients with ceftazodime-nonsusceptible pathogens, and may offer an alternative to carbapenems in this setting.
Journal ArticleDOI
Global epidemiology of urinary tract infections.
TL;DR: The most recent global epidemiological data of UTIs have been summarized and it is challenging to provide with an exact frequency of UTI, which varies according to geographical setting.